The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib

Sarcomas are a diverse set of malignancies. For soft tissue sarcomas, the kinase and chaperone inhibitor pazopanib is a standard of care therapeutic. Previously, we demonstrated that HDAC inhibitors enhanced pazopanib lethality against sarcoma and other tumor cell types in vitro and in vivo. The pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657367/
https://www.ncbi.nlm.nih.gov/pubmed/31380285
http://dx.doi.org/10.3389/fonc.2019.00650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657367/
https://www.ncbi.nlm.nih.gov/pubmed/31380285
http://dx.doi.org/10.3389/fonc.2019.00650

Ejemplares similares